The index is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development.
As of 03/22/2019
Mutual Fund to ETF Converter Tool
ETFs tracking the LifeSci Biotechnology Clinical Trials Index are presented in the following table.
The following table presents historical return data for ETFs tracking the LifeSci Biotechnology Clinical Trials Index.
The table below includes fund flow data for all U.S. listed Highland Capital Management ETFs. Total fund flow is the capital inflow into an ETF minus the capital outflow from the ETF for a particular time period.
Fund Flows in millions of U.S. Dollars.
The following table presents expense information for ETFs tracking the LifeSci Biotechnology Clinical Trials Index.
The following table presents dividend information for ETFs tracking the LifeSci Biotechnology Clinical Trials Index, including yield and dividend date.
The following table presents holdings data for all ETFs tracking the LifeSci Biotechnology Clinical Trials Index. For more detailed holdings data for an ETF click the ‘View’ link in the right column.
The following table presents sortable tax data for ETFs currently tracking the LifeSci Biotechnology Clinical Trials Index.
The following table presents certain technical indicators for ETFs tracking the LifeSci Biotechnology Clinical Trials Index. To see complete technical metrics click the ‘View’ link in the right column.
The following table presents links to in-depth analysis for ETFs tracking the LifeSci Biotechnology Clinical Trials Index.
The following table presents a proprietary ETFdb rating for ETFs tracking the LifeSci Biotechnology Clinical Trials Index.
| Symbol | ETF Name | Asset Class | Total Assets* | YTD | Avg Volume | Previous Closing Price | 1-Day Change | Overall Rating | 1 Week | 4 Week | 1 Year | 3 Year | 5 Year | YTD FF | 1 Week FF | 4 Week FF | 1 Year FF | 3 Year FF | 5 Year FF | ETFdb.com Category | Inception | ER | Commission Free | Annual Dividend Rate | Dividend Date | Dividend | Annual Dividend Yield % | P/E Ratio | Beta | # of Holdings | % In Top 10 | Complete | ST Cap Gain Rate | LT Cap Gain Rate | Tax Form | Lower Bollinger | Upper Bollinger | Support 1 | Resistance 1 | RSI | Advanced | Fact Sheet | ETF Holdings | Chart | ETF Home Page | Head-To-Head | Liquidity Rating | Expenses Rating | Returns Rating | Volatility Rating | Dividend Rating | Concentration Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | Equity | $30,557 | 18.8% | 12,315.0 | $27.59 | -5.12% | -1.8% | 6.1% | -18.6% | 50.6% | N/A | Health & Biotech Equities | 2014-12-16 | 0.79% | N/A | $0.00 | 2017-12-20 | $0.30 | 0.00% | 27.2 | 1.97 | 96 | 18.1% | View | 35% | 15% | 1099 | $26.05 | $29.05 | $27.13 | $28.52 | 53.99 | View | View | View | View | View | View | N/A | C |
Sort By:
ETFdb staff has allocated each ETF in the ETF database, as well as each index, to a single ‘best-fit’ ETFdb.com Category. Other ETFs in the Health & Biotech Equities ETFdb.com Category are presented in the following table.
* Assets in thousands of U.S. Dollars. Assets and Average Volume as of 2019-03-22 20:15:03 UTC
Historical return data for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Fund flow information for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Expense information for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Dividend information for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Holdings data for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Tax Rate data for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Technical information for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Links to analysis of other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
Links to a proprietary ETFdb rating for other ETFs in the Health & Biotech Equities ETFdb.com Category is presented in the following table.
| Symbol | ETF Name | Asset Class | Total Assets* | YTD | Avg Volume | Previous Closing Price | 1-Day Change | Overall Rating | 1 Week | 4 Week | 1 Year | 3 Year | 5 Year | YTD FF | 1 Week FF | 4 Week FF | 1 Year FF | 3 Year FF | 5 Year FF | ETFdb.com Category | Inception | ER | Commission Free | Annual Dividend Rate | Dividend Date | Dividend | Annual Dividend Yield % | P/E Ratio | Beta | # of Holdings | % In Top 10 | Complete | ST Cap Gain Rate | LT Cap Gain Rate | Tax Form | Lower Bollinger | Upper Bollinger | Support 1 | Resistance 1 | RSI | Advanced | Fact Sheet | ETF Holdings | Chart | ETF Home Page | Head-To-Head | Liquidity Rating | Expenses Rating | Returns Rating | Volatility Rating | Dividend Rating | Concentration Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR Fund | Equity | $19,642,120 | 5.1% | 10,611,431.0 | $90.62 | -1.82% | -1.5% | -1.7% | 13.2% | 41.2% | 68.0% | Health & Biotech Equities | 1998-12-16 | 0.13% | N/A | $1.40 | 2019-03-15 | $0.34 | 1.52% | 16.6 | 1.00 | 63 | 51.6% | View | 35% | 15% | 1099 | $89.33 | $93.31 | $90.07 | $91.71 | 49.53 | View | View | View | View | View | View | A+ | A | |||||||||||
| VHT | Vanguard Healthcare ETF | Equity | $9,417,676 | 6.8% | 316,526.0 | $170.46 | -2.07% | -1.6% | -1.4% | 12.8% | 46.2% | 70.8% | Health & Biotech Equities | 2004-01-30 | 0.10% | Vanguard | $2.94 | 2019-03-21 | $1.11 | 1.69% | 28.7 | 1.02 | 356 | 44.2% | View | 35% | 15% | 1099 | $167.85 | $175.79 | $169.28 | $172.72 | 50.12 | View | View | View | View | View | View | A | A+ | |||||||||||
| IBB | iShares Nasdaq Biotechnology ETF | Equity | $8,388,993 | 12.2% | 2,372,897.0 | $108.17 | -3.39% | -5.3% | -2.3% | 0.2% | 27.4% | 33.0% | Health & Biotech Equities | 2001-02-05 | 0.47% | N/A | $0.19 | 2018-09-26 | $0.03 | 0.17% | 19.7 | 1.38 | 221 | 51.3% | View | 35% | 15% | 1099 | $108.73 | $115.93 | $106.95 | $110.55 | 44.68 | View | View | View | View | View | View | A | B | |||||||||||
| XBI | SPDR S&P Biotech ETF | Equity | $4,405,583 | 22.4% | 5,184,081.0 | $87.86 | -4.42% | -3.7% | 2.5% | -2.5% | 74.0% | 76.2% | Health & Biotech Equities | 2006-02-06 | 0.35% | N/A | $0.20 | 2018-12-21 | $0.01 | 0.22% | 17.3 | 1.65 | 120 | 16.6% | View | 35% | 15% | 1099 | $86.58 | $92.99 | $86.57 | $90.37 | 51.43 | View | View | View | View | View | View | A | A- | |||||||||||
| IHI | iShares U.S. Medical Devices ETF | Equity | $3,628,907 | 14.0% | 247,529.0 | $227.71 | -2.48% | -1.3% | 1.4% | 23.8% | 92.5% | 141.4% | Health & Biotech Equities | 2006-05-05 | 0.43% | N/A | $0.53 | 2018-12-17 | $0.29 | 0.23% | 41.1 | 0.99 | 56 | 70.1% | View | 35% | 15% | 1099 | $221.83 | $232.92 | $225.81 | $231.52 | 56.57 | View | View | View | View | View | View | B+ | B+ | |||||||||||
| FBT | First Trust Amex Biotechnology Index | Equity | $3,087,063 | 17.3% | 170,087.0 | $145.66 | -3.52% | -3.8% | 0.5% | 7.3% | 70.8% | 83.1% | Health & Biotech Equities | 2006-06-23 | 0.56% | N/A | $0.00 | 2015-09-23 | $0.02 | 0.00% | 19.7 | 1.38 | 31 | 38.8% | View | 35% | 15% | 1099 | $143.67 | $153.50 | $144.03 | $148.92 | 49.70 | View | View | View | View | View | View | A- | C+ | |||||||||||
| IYH | iShares U.S. Healthcare ETF | Equity | $2,410,854 | 6.1% | 136,197.0 | $191.40 | -1.98% | -1.6% | -1.5% | 13.0% | 43.8% | 68.3% | Health & Biotech Equities | 2000-06-12 | 0.43% | N/A | $3.56 | 2019-03-20 | $0.52 | 1.82% | 26.2 | 1.00 | 128 | 47.7% | View | 35% | 15% | 1099 | $188.53 | $197.25 | $190.26 | $193.67 | 49.86 | View | View | View | View | View | View | B+ | B | |||||||||||
| FXH | First Trust Health Care AlphaDEX Fund | Equity | $2,181,566 | 10.5% | 212,029.0 | $76.09 | -2.37% | -1.2% | -0.7% | 8.8% | 40.3% | 47.6% | Health & Biotech Equities | 2007-05-08 | 0.63% | N/A | $0.00 | 2013-06-21 | $0.01 | 0.00% | 24.6 | 0.97 | 74 | 24.3% | View | 35% | 15% | 1099 | $74.13 | $78.40 | $75.57 | $77.14 | 51.94 | View | View | View | View | View | View | A | C+ | |||||||||||
| IXJ | iShares Global Healthcare ETF | Equity | $2,122,993 | 6.6% | 296,129.0 | $60.39 | -1.76% | -1.6% | -0.6% | 12.0% | 34.0% | 46.2% | Health & Biotech Equities | 2001-11-13 | 0.47% | N/A | $1.53 | 2018-12-28 | $0.66 | 2.48% | 24.3 | 0.90 | 114 | 39.6% | View | 35% | 15% | 1099 | $59.69 | $61.90 | $60.11 | $60.95 | 51.09 | View | View | View | View | View | View | B+ | B | |||||||||||
| FHLC | Fidelity MSCI Health Care Index ETF | Equity | $1,612,443 | 6.9% | 342,647.0 | $44.00 | -2.07% | -1.5% | -1.4% | 12.7% | 46.3% | 70.6% | Health & Biotech Equities | 2013-10-21 | 0.08% | Fidelity | $0.91 | 2019-03-15 | $0.16 | 2.03% | 28.9 | 1.01 | 347 | 44.1% | View | 35% | 15% | 1099 | $43.32 | $45.36 | $43.70 | $44.58 | 50.14 | View | View | View | View | View | View | N/A | A | |||||||||||
| Click Here to Join to ETFdb Pro for 14 Days Free, Export This Data & So Much More | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Smart beta exchange-traded funds (ETFs) have become increasingly popular over the past several years. In fact, BlackRock projects that smart beta ETFs will grow at a 20% annual pace to $1 trillion in assets under management by 2020.
Smart beta exchange-traded funds (ETFs) have become a popular way for investors to target specific portfolio outcomes like reduced risk, enhanced returns or higher income at a lower cost than actively managed funds.
With the rise of bonds ETFs investors now have more ways than ever before to improve, as well as damage, their fixed income portfolios.
